Loading
R-Pharm
R-Pharm is a large private Russian pharmaceutical company that manufactures and licenses medicines including cancer generics and biosimilars, and sponsors phase 3 trials of them in Russia.
Also called: R-Pharm JSCР-Фарм
Overview
R-Pharm, founded in Moscow in 2001, is one of Russia's largest pharmaceutical companies, spanning manufacturing, distribution and development, including generic and biosimilar cancer medicines and licensed products for the Russian market. It appears as lead sponsor of a number of phase 3 cancer trials on ClinicalTrials.gov, mostly comparative studies of its versions of established drugs. OnCo records it so that those trials resolve to a sponsor page.
Headquarters
Moscow, RU
Scorecard
All companies#402of 1245 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Products
1Phase 3monoclonal antibody
RPH-051 is an experimental monoclonal antibody from R-Pharm in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.
Connected
6Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
drugs
Phase 3monoclonal antibody
terms
trials
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerA Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial CancerA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
r-pharm.com · 1
Wikipedia · 1
A source that has moved or gone is reported by the weekly link check. /audit/